[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616886":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":16,"locations":27,"responsibleParty":48,"collaborators":16,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":16,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":16,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":16,"overallStatus":30,"whyStopped":16,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Athletic Greens International","INDUSTRY",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Sleep Supplement","EXPERIMENTAL",[12],"Dietary Supplement: Sleep Supplement",{"label":14,"type":15,"description":14,"interventionNames":16},"Usual Diet","NO_INTERVENTION",null,[18],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":16},"DIETARY_SUPPLEMENT","Powdered sleep supplement",[9],[23],{"name":24,"affiliation":25,"role":26},"Philip Sapp, PhD, MS","Athletic Greens - AG1","PRINCIPAL_INVESTIGATOR",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Alethios (Virtual Study Platform)","RECRUITING","San Francisco","California","94117","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-122.41942,37.77493,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":16,"email":47},"Zeenia Framroze","CONTACT","6502068006","support@alethios.com",{"type":49,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100616886","sleep-and-morning-wellbeing-study-100616886",false,"NCT07311434","Sleep and Morning Wellbeing Study","Evaluation of Perceived Outcomes With AGZ: A Randomized, Controlled, Consumer Perception Study","Inclusion Criteria:\n\n* Male or female.\n* Age 25-59 years.\n* BMI ≥18.5 and ≤29.9 kg\u002Fm².\n* Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night.\n* RU-SATED score ≤17.\n* Willing and able to follow the study protocol.\n* Willing to discontinue any other supplements (including nootropics, adaptogens, calming herbs), medications, herbal remedies, or over-the-counter sleep medications (e.g., zolpidem, diphenhydramine, Benadryl, ZzzQuil, Unisom, magnesium or melatonin products) used to assist with sleep during the study.\n* Agree to limit alcohol intake within approximately 4 hours of bedtime throughout participation.\n* Agree to limit caffeine intake to ≤400 mg\u002Fday (about 3-4 cups of coffee) and avoid ingestion of caffeine-containing products after 2:00 PM during the study period.\n* Generally healthy and not living with any uncontrolled chronic disease.\n* Resides in the United States.\n* Willing to discontinue any restricted products and adhere to all required study assessments.\n\nExclusion Criteria:\n\n* Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea).\n* Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.\n\nWomen currently undergoing perimenopause or experiencing vasomotor symptoms (e.g., night sweats).\n\n* Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.\n* Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.\n* Diagnosed neurodegenerative or chronic pain disorders, including Parkinson's disease, Alzheimer's disease, or uncontrolled fibromyalgia.\n* Regular prescribed stimulant use (e.g., amphetamines such as Adderall\u002FVyvanse; methylphenidate such as Ritalin\u002FConcerta; modafinil\u002Farmodafinil).\n* Current use of CNS-activating antidepressants (bupropion, fluoxetine, venlafaxine, sertraline).\n* Current or recent use of cannabis or THC-containing products (recreational or medicinal marijuana, CBD with measurable THC, synthetic cannabinoids) within the past 30 days.\n* Employment in jobs disrupting nighttime sleep (e.g., night shift, rotating shift, excessive travel).\n* Current use of prescription sleep aids.\n* Introduction of any new sleep-related supplements, medications, herbal remedies, or melatonin products during the study.\n* Use of any prescription or OTC products with sedative properties (e.g., melatonin, diphenhydramine, doxylamine, valerian, ZzzQuil, Advil PM) within 4 weeks prior to enrollment or habitual use ≥3 times per week prior to enrollment unless investigator-approved.\n* Allergy or sensitivity to any study product ingredients.\n* Pregnant, breastfeeding, or trying to conceive during the study period.\n* History of substance abuse.\n* Heavy alcohol use (≥8 drinks\u002Fweek for women or ≥15 drinks\u002Fweek for men).\n* Participation in another research study now or within the next 7 weeks.\n* Any condition or behavior that, in the investigator's judgment, may interfere with study participation or data integrity.",true,"ALL","22 Years","59 Years",{"count":62,"type":63},300,"ESTIMATED","INTERVENTIONAL",[66],"NA","The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.",[69,70,71,72],"Sleep","Relaxation","Stress","Daytime Sleepiness","2026-02-10",{"date":75,"type":76},"2026-02-11","ACTUAL",{"date":78,"type":76},"2026-01-20",{"date":80,"type":63},"2026-06-01",{"name":5,"class":6},1]